Cuban President Miguel Díaz-Canel Bermúdez emphasized on Tuesday the importance of integrating Biomodulin T into primary health care across Cuban communities. During a meeting with health experts at the Palace of the Revolution, he urged that medical professionals be adequately trained to prescribe this innovative treatment. The discussion highlighted the significant role of Biomodulin T, a bovine thymus extract-based drug, in addressing immune dysfunction and recurrent infections, particularly among the elderly. Clinical trials involving nearly 9,000 nursing home residents demonstrated a remarkable reduction in acute respiratory infections (ARI) by over five times, and a 50% decrease in mortality risk compared to those outside such facilities. The drug also showed a 70% reduction in respiratory infection incidence among the elderly, a leading cause of death in Cuban nursing homes. Additionally, Biomodulin T has proven effective in oncology, rejuvenating patients’ immune systems when combined with chemotherapy and immunotherapy. It has also been successful in treating thymic hypoplasia in children, with 83% of treated children achieving normalized thymus size and function, and 71% showing clinical improvement. Given these promising results, President Díaz-Canel called for expedited efforts to incorporate Biomodulin T into national health strategies, especially in light of Cuba’s aging population. The drug, which gained prominence during the COVID-19 pandemic with over 1.9 million units distributed and more than 238,000 patients treated, has been recognized with two awards from the Academy of Sciences in 2022 for its efficacy in treating lung cancer and its immunomodulatory effects in older adults.